- 1.
Creech O, Krementz ET, Ryan RF et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616–32. [PubMed][CrossRef]
- 2.
Tsagozis P, Brosjö O, Skorpil M. Preoperative radiotherapy of soft-tissue sarcomas: surgical and radiologic parameters associated with local control and survival. Clin Sarcoma Res 2018; 8: 19. [PubMed][CrossRef]
- 3.
Nieweg OE, Kroon BB. Isolated limb perfusion with melphalan for melanoma. J Surg Oncol 2014; 109: 332–7. [PubMed][CrossRef]
- 4.
Lienard D, Ewalenko P, Delmotte JJ et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10: 52–60. [PubMed][CrossRef]
- 5.
Eggermont AM, Schraffordt Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756–64. [PubMed][CrossRef]
- 6.
Ahmed AE, Hsu TF, el-Azhary RA et al. Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. Cancer Chemother Pharmacol 1982; 8: 271–6. [PubMed][CrossRef]
- 7.
Johansson J, Kiffin R, Andersson A et al. Isolated limb perfusion with melphalan triggers immune activation in melanoma patients. Front Oncol 2018; 8: 570. [PubMed][CrossRef]
- 8.
de Wilt JH, ten Hagen TL, de Boeck G et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82: 1000–3. [PubMed][CrossRef]
- 9.
Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 2010; 15: 416–27. [PubMed][CrossRef]
- 10.
Cornett WR, McCall LM, Petersen RP et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24: 4196–201. [PubMed][CrossRef]
- 11.
Madu MF, Deken MM, van der Hage JA et al. Isolated limb perfusion for melanoma is safe and effective in elderly patients. Ann Surg Oncol 2017; 24: 1997–2005. [PubMed][CrossRef]
- 12.
Hildebrandt B, Wust P, Ahlers O et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33–56. [PubMed][CrossRef]
- 13.
Wieberdink J, Benckhuysen C, Braat RP et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–10. [PubMed][CrossRef]
- 14.
Grunhagen DJ, de Wilt JH, Graveland WJ et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106: 1776–84. [PubMed][CrossRef]
- 15.
Möller MG, Lewis JM, Dessureault S et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008; 24: 275–89. [PubMed][CrossRef]
- 16.
Martin-Tellez KS, van Houdt WJ, van Coevorden F et al. Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 2020; 88: 102058. [PubMed][CrossRef]
- 17.
Olofsson R, Bergh P, Berlin O et al. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2012; 19: 1800–7. [PubMed][CrossRef]
- 18.
Deroose JP, Eggermont AM, van Geel AN et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011; 29: 4036–44. [PubMed][CrossRef]
- 19.
Larkin J, Chiarion-Sileni V, Gonzalez R et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535–46. [PubMed][CrossRef]
- 20.
Robert C, Grob JJ, Stroyakovskiy D et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381: 626–36. [PubMed][CrossRef]
- 21.
Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer, 22.5.2020. https://www.helsebiblioteket.no/retningslinjer/maligne-melanomer Lest 21.6.2021.
- 22.
Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av sarkom, 10.4.2018. https://www.helsebiblioteket.no/retningslinjer/sarkomer/ Lest 21.6.2021.
- 23.
Noorda EM, Vrouenraets BC, Nieweg OE et al. Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol 2004; 11: 837–45. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.